Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin Osterhout is active.

Publication


Featured researches published by Martin Osterhout.


Bioorganic & Medicinal Chemistry Letters | 2001

p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.

Aniko Redman; Jeffrey S Johnson; Robert Dally; Steve Swartz; Hanno Wild; Holger Paulsen; Yolanda V Caringal; David E. Gunn; Joel Renick; Martin Osterhout; Jill Kingery-Wood; Roger A. Smith; Wendy Lee; Jacques Dumas; Scott Wilhelm; Timothy J Housley; Ajay Bhargava; Gerald Ranges; Alka Shrikhande; Deborah Young; Michael Bombara; William J. Scott

Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.


Bioorganic & Medicinal Chemistry Letters | 2002

Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.

Jacques Dumas; Holia Hatoum-Mokdad; Robert Sibley; Roger A. Smith; William J. Scott; Uday Khire; Wendy Lee; Jill E. Wood; Donald John Wolanin; Jeffrey Cooley; Donald Bankston; Aniko Redman; Robert W. Schoenleber; Yolanda V Caringal; David E. Gunn; Romulo Romero; Martin Osterhout; Holger Paulsen; Timothy J Housley; Scott Wilhelm; John Pirro; Du-Shieng Chien; Gerald Ranges; Alka Shrikhande; Andrew Muzsi; Elizabeth Bortolon; Jean Wakefield; Cynthia Gianpaolo Ostravage; Ajay Bhargava; Thuy Chau

Inhibitors of the MAP kinase p38 provide a novel approach for the treatment of osteoporosis, inflammatory disorders, and cancer. We have identified N-(3-tert-butyl-1-methyl-5-pyrazolyl)-N-(4-(4-pyridinylmethyl)phenyl)urea as a potent and selective p38 kinase inhibitor in biochemical and cellular assays. This compound is orally active in two acute models of cytokine release (TNF-induced IL-6 and LPS-induced TNF) and a chronic model of arthritis (20-day murine collagen-induced arthritis).


Bioorganic & Medicinal Chemistry Letters | 2002

Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis

Roger A. Smith; Donald L. Hertzog; Martin Osterhout; Gaetan Ladouceur; Mary Korpusik; Mark Bobko; J.Howard Jones; Kathleen M. Phelan; Romulo Romero; Thomas Hundertmark; Margit MacDougall; James N. Livingston; William R. Schoen

A narrow structure-activity relationship was established for the 4-aryl group in 4-aryl-pyridine glucagon antagonists, with only small substituents being well-tolerated, and only at the 3- and 4-positions. However, substitution with a 2-hydroxy group gave a ca. 3-fold increase in activity (e.g., 4-fluoro-2-hydroxy analogue 33, IC50=190 nM). For efficient preparation of 2-substituted phenylpyridines, a novel synthesis via pyrones and 4-methoxy-pyridines was developed.


Bioorganic & Medicinal Chemistry Letters | 2002

Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists

Gaetan Ladouceur; James H. Cook; Donald L. Hertzog; J.Howard Jones; Thomas Hundertmark; Mary Korpusik; Timothy G. Lease; James N. Livingston; Margit MacDougall; Martin Osterhout; Kathleen M. Phelan; Romulo Romero; William R. Schoen; Chunning Shao; Roger A. Smith

Optimized substituent patterns in 4-aryl-pyridine glucagon receptor antagonists were merged to produce highly potent derivatives containing both a 3-[(1R)-hydroxyethyl] and a 2-hydroxy group. Due to restricted rotation of the phenyl-pyridine bond, these analogues exist as four isomers. A diastereoselective methylcopper reaction was developed to facilitate the synthesis, and single isomers were isolated with activities in the range IC(50)=10-25 nM.


Archive | 1998

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Timothy B. Lowinger; William J. Scott; Roger A. Smith; Jill E. Wood; David E. Gunn; Holia Hatoum-Mokdad; Marell Rodriguez; Robert Sibley; Ming Wang; Tiffany Turner; Catherine Brennan


Archive | 1998

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Timothy B. Lowinger; Bernd Riedl; William J. Scott; Roger A. Smith; Jill E. Wood; David E. Gunn; Ming Wang; Tiffany Turner; Catherine Brennan


Archive | 1997

Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents

Gunter Schmidt; Rolf Angerbauer; Arndt Brandes; Matthias Dr. Müller-Gliemann; Hilmar Bischoff; Delf Schmidt; Stefan Wohlfeil; William R. Schoen; Gaetan Ladouceur; James H. Cook; Timothy G. Lease; Donald John Wolanin; Richard H. Kramss; Donald L. Hertzog; Martin Osterhout


Archive | 1998

Amide derivatives as selective neuropeptide y receptor antagonists

Richard Connell; Timothy G. Lease; Gaetan Ladouceur; Martin Osterhout


Archive | 1998

Amides as npy5 receptor antagonists

Richard Connell; Timothy G. Lease; Gaetan Ladouceur; Martin Osterhout


Archive | 1998

HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN

Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Bruno Lowinger; Bernd Riedl; J Scott; A Smith; E Wood; David E. Gunn; Holia Hatoum-Mokdad; Robert Sibley; Ming Wang; Tiffany Turner; Catherine Brennan

Collaboration


Dive into the Martin Osterhout's collaboration.

Researchain Logo
Decentralizing Knowledge